Our top pick for
Renalytix Plc is a diagnostics & research business based in the US. Renalytix shares (RNLX) are listed on the NASDAQ and all prices are listed in US Dollars. Renalytix employs 8 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$24.42|
|52-week range||$10.31 - $35.71|
|50-day moving average||$21.61|
|200-day moving average||$27.32|
|Wall St. target price||$38.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.80|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||13.79%|
|1 month (2021-09-20)||32.14%|
|3 months (2021-07-20)||-14.07%|
|6 months (2021-04-20)||-6.04%|
|1 year (2020-10-20)||122.00%|
|2 years (2019-10-16)||N/A|
|3 years (2018-10-16)||N/A|
|5 years (2016-10-16)||N/A|
|Revenue TTM||$1 million|
|Gross profit TTM||$0|
|Return on assets TTM||-31.61%|
|Return on equity TTM||-56.56%|
|Market capitalisation||$890.7 million|
TTM: trailing 12 months
There are currently 491,886 Renalytix shares held short by investors – that's known as Renalytix's "short interest". This figure is 45.3% up from 338,452 last month.
There are a few different ways that this level of interest in shorting Renalytix shares can be evaluated.
Renalytix's "short interest ratio" (SIR) is the quantity of Renalytix shares currently shorted divided by the average quantity of Renalytix shares traded daily (recently around 113599.53810624). Renalytix's SIR currently stands at 4.33. In other words for every 100,000 Renalytix shares traded daily on the market, roughly 4330 shares are currently held short.
However Renalytix's short interest can also be evaluated against the total number of Renalytix shares, or, against the total number of tradable Renalytix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Renalytix's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Renalytix shares in existence, roughly 10 shares are currently held short) or 0.0152% of the tradable shares (for every 100,000 tradable Renalytix shares, roughly 15 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Renalytix.
Find out more about how you can short Renalytix stock.
We're not expecting Renalytix to pay a dividend over the next 12 months.
Over the last 12 months, Renalytix's shares have ranged in value from as little as $10.31 up to $35.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Renalytix's is 1.2429. This would suggest that Renalytix's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.